

Steven G Gray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5196196/publications.pdf>

Version: 2024-02-01

168
papers

5,424
citations

109321

35
h-index

91884

69
g-index

180
all docs

180
docs citations

180
times ranked

8256
citing authors

#	ARTICLE	IF	CITATIONS
1	The Human Histone Deacetylase Family. <i>Experimental Cell Research</i> , 2001, 262, 75-83.	2.6	507
2	Circular RNAs: Biogenesis, Function and Role in Human Diseases. <i>Frontiers in Molecular Biosciences</i> , 2017, 4, 38.	3.5	449
3	Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2005, 164, 10-21.	2.3	266
4	Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature. <i>PLoS ONE</i> , 2013, 8, e54193.	2.5	221
5	Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. <i>Oncogene</i> , 2003, 22, 6810-6818.	5.9	192
6	NF- κ B regulation: the nuclear response. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 631-643.	3.6	154
7	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. <i>Lung Cancer</i> , 2012, 76, 19-25.	2.0	153
8	Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells. <i>Cancers</i> , 2017, 9, 38.	3.7	143
9	Lung cancer stem cells: The root of resistance. <i>Cancer Letters</i> , 2016, 372, 147-156.	7.2	130
10	Role of histone and transcription factor acetylation in diabetes pathogenesis. <i>Diabetes/Metabolism Research and Reviews</i> , 2005, 21, 416-433.	4.0	129
11	Functional Characterization of JMJD2A, a Histone Deacetylase- and Retinoblastoma-binding Protein. <i>Journal of Biological Chemistry</i> , 2005, 280, 28507-28518.	3.4	122
12	The RNA Methyltransferase NSUN2 and Its Potential Roles in Cancer. <i>Cells</i> , 2020, 9, 1758.	4.1	105
13	Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p161. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 730-735.	3.6	97
14	Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple Sclerosis. <i>Epigenetics</i> , 2006, 1, 67-75.	2.7	94
15	Histone Acetylation / Deacetylation and Cancer: An 'Open' and 'Shut' Case?. <i>Current Molecular Medicine</i> , 2001, 1, 401-429.	1.3	87
16	Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 2800-2821.	3.6	86
17	The emerging role of microRNAs in resistance to lung cancer treatments. <i>Cancer Treatment Reviews</i> , 2015, 41, 160-169.	7.7	83
18	Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p16. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 730-735.	3.6	76

#	ARTICLE	IF	CITATIONS
19	Receptor tyrosine kinases and their activation in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 446-461.	3.3	69
20	BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. <i>Cancer Letters</i> , 2018, 428, 117-126.	7.2	69
21	Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. <i>Scientific Reports</i> , 2019, 9, 10739.	3.3	69
22	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscope Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	1.1	66
23	Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer. <i>Molecular Cancer</i> , 2015, 14, 45.	19.2	64
24	Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. <i>Oncotarget</i> , 2017, 8, 72544-72563.	1.8	60
25	Targeting oxidative stress in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1225-1245.	3.4	58
26	Altered expression of members of the IGF-axis in hepatoblastomas. <i>British Journal of Cancer</i> , 2000, 82, 1561-1567.	6.4	54
27	Effects of Cell Density and Trichostatin A on the Expression of HDAC1 and p57Kip2 in Hep 3B Cells. <i>Biochemical and Biophysical Research Communications</i> , 1998, 245, 423-427.	2.1	47
28	Epigenetics Underpinning the Regulation of the CXC (ELR+) Chemokines in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2011, 6, e14593.	2.5	44
29	Epigenetic treatment of neurological disease. <i>Epigenomics</i> , 2011, 3, 431-450.	2.1	43
30	Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. <i>Translational Lung Cancer Research</i> , 2020, 9, S100-S119.	2.8	43
31	Targeting histone deacetylases for the treatment of disease. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 826-852.	3.6	41
32	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscope Project. <i>Lung Cancer</i> , 2019, 131, 95-103.	2.0	40
33	Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. <i>European Journal of Cancer</i> , 2012, 48, 1096-1107.	2.8	39
34	IGF-I, IGF-II, and Insulin Stimulate Different Gene Expression Responses through Binding to the IGF-I Receptor. <i>Frontiers in Endocrinology</i> , 2013, 4, 98.	3.5	39
35	IGF-II Enhances Trichostatin A-Induced TGF β 1 and p21Waf1, Cip1, Sdi1 Expression in Hep3B Cells. <i>Experimental Cell Research</i> , 1999, 253, 618-628.	2.6	36
36	IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. <i>European Journal of Cancer</i> , 2011, 47, 1908-1918.	2.8	36

#	ARTICLE	IF	CITATIONS
37	The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer. <i>Cancers</i> , 2011, 3, 1426-1453.	3.7	35
38	Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. <i>Oncogenesis</i> , 2013, 2, e72-e72.	4.9	34
39	BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. <i>Journal of Pathology</i> , 2012, 227, 200-208.	4.5	33
40	IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 83-90.	2.0	33
41	Carcinogenesis in prostate cancer: The role of long non-coding RNAs. <i>Non-coding RNA Research</i> , 2018, 3, 29-38.	4.6	33
42	Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM). <i>PLoS ONE</i> , 2013, 8, e70940.	2.5	33
43	Tissue context-activated telomerase in human epidermis correlates with little age-dependent telomere loss. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 297-308.	3.8	32
44	The SCBS cell strain as a model for the in vitro study of obesity and cancer. <i>Clinical and Translational Oncology</i> , 2012, 14, 774-782.	2.4	32
45	Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma.. <i>International Journal of Molecular Medicine</i> , 2000, 5, 33-41.	4.0	31
46	Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. <i>International Journal of Molecular Medicine</i> , 2012, 30, 1505-1511.	4.0	31
47	Comparative genomic hybridization reveals population-based genetic alterations in hepatoblastomas. <i>British Journal of Cancer</i> , 2000, 83, 1020-1025.	6.4	30
48	Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression. <i>PLoS ONE</i> , 2012, 7, e52753.	2.5	30
49	KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2016, 48, 1290-1296.	3.3	30
50	Methylation Changes in the Human IGF2 P3 Promoter Parallel IGF2 Expression in the Primary Tumor, Established Cell Line, and Xenograft of a Human Hepatoblastoma. <i>Experimental Cell Research</i> , 2001, 270, 88-95.	2.6	29
51	Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma. <i>JAMA Network Open</i> , 2022, 5, e221490.	5.9	29
52	The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1339-1356.	3.4	28
53	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays TM and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. <i>Modern Pathology</i> , 2020, 33, 792-801.	5.5	28
54	The Insulin-like Growth Factors and Insulin-signalling Systems: An Appealing Target for Breast Cancer Therapy?. <i>Hormone and Metabolic Research</i> , 2003, 35, 857-871.	1.5	27

#	ARTICLE	IF	CITATIONS
55	Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer. Expert Review of Gastroenterology and Hepatology, 2019, 13, 247-256.	3.0	27
56	Targeting Histone Deacetylases for the Treatment of Huntington's Disease. CNS Neuroscience and Therapeutics, 2010, 16, 348-361.	3.9	26
57	Epigenetic Regulation of Glucose Transporters in Non-Small Cell Lung Cancer. Cancers, 2011, 3, 1550-1565.	3.7	26
58	Long noncoding RNAs in liver cancer: what we know in 2014. Expert Opinion on Therapeutic Targets, 2014, 18, 1207-1218.	3.4	26
59	Targeting NF- κ B-mediated inflammatory pathways in cisplatin-resistant NSCLC. Lung Cancer, 2019, 135, 217-227.	2.0	25
60	Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. Journal of Nanobiotechnology, 2021, 19, 71.	9.1	24
61	Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. European Journal of Cancer, 2009, 45, 3087-3097.	2.8	23
62	Targeting Huntington's disease through histone deacetylases. Clinical Epigenetics, 2011, 2, 257-277.	4.1	23
63	Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer. Cancer, 2011, 117, 5121-5132.	4.1	23
64	Methylation, gene expression and the chromatin connection in cancer (review). International Journal of Molecular Medicine, 1999, 4, 333-50.	4.0	22
65	Endoplasmic reticulum stress "A double edged sword for α -1 antitrypsin deficiency hepatotoxicity. International Journal of Biochemistry and Cell Biology, 2008, 40, 1403-1414.	2.8	21
66	Perspectives on epigenetic-based immune intervention for rheumatic diseases. Arthritis Research and Therapy, 2013, 15, 207.	3.5	21
67	Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. BMC Pulmonary Medicine, 2021, 21, 148.	2.0	20
68	Human Histone Deacetylase 2, HDAC2 (Human RPD3), Is Localized to 6q21 by Radiation Hybrid Mapping. Genomics, 1998, 52, 245-246.	2.9	19
69	Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2009, 9, 84-107.	1.2	18
70	Sinapinic and protocatechuic acids found in rapeseed: isolation, characterisation and potential benefits for human health as functional food ingredients. Irish Journal of Agricultural and Food Research, 2017, 56, 104-119.	0.4	17
71	Induction of protein citrullination and auto-antibodies production in murine exposed to nickel nanomaterials. Scientific Reports, 2018, 8, 679.	3.3	17
72	In Arrayed Ranks: Array Technology in the Study of Mesothelioma. Journal of Thoracic Oncology, 2009, 4, 411-425.	1.1	16

#	ARTICLE	IF	CITATIONS
73	Non-coding RNA repertoires in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2015, 90, 417-426.	2.0	16
74	Extraction and Quantification of Sinapinic Acid from Irish Rapeseed Meal and Assessment of Angiotensin-I Converting Enzyme (ACE-I) Inhibitory Activity. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 6886-6892.	5.2	16
75	SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 18605.	3.3	16
76	Promoter-specific transcription of the IGF2 gene: a novel rapid, non-radioactive and highly sensitive protocol for mRNA analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 439, 803-807.	2.8	15
77	Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?. <i>Current Diabetes Reviews</i> , 2009, 5, 201-209.	1.3	15
78	IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 162.	2.8	15
79	RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies. <i>Diagnostics</i> , 2018, 8, 60.	2.6	15
80	In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM). <i>International Journal of Molecular Sciences</i> , 2018, 19, 1297.	4.1	15
81	Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells. <i>Oncolmmunology</i> , 2018, 7, e1428156.	4.6	14
82	Insulin receptor substrates-5 and -6 are poor substrates for the insulin receptor. <i>Molecular Medicine Reports</i> , 2009, 3, 189-93.	2.4	13
83	Hemochromatosis: As a conformational disorder. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 2094-2097.	2.8	13
84	EGFR-AS1/HIF2A regulates the expression of FOXP3 to impact the cancer stemness of smoking-related non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985522.	3.2	13
85	Expression levels of insulin-like growth factor binding proteins and insulin receptor isoforms in hepatoblastomas. <i>Cancer Letters</i> , 2001, 162, 253-260.	7.2	12
86	Epigenetic-based immune intervention for rheumatic diseases. <i>Epigenomics</i> , 2014, 6, 253-271.	2.1	12
87	VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach. <i>Epigenomics</i> , 2015, 7, 897-910.	2.1	12
88	Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2017, 50, 1044-1052.	3.3	12
89	Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin. <i>Translational Oncology</i> , 2021, 14, 101025.	3.7	12
90	Histone deacetylase 3 represses HTLV-1 tax transcription. <i>Oncology Reports</i> , 2006, 16, 581-5.	2.6	12

#	ARTICLE	IF	CITATIONS
91	Modulation of Splicing Events in Histone Deacetylase 3 by Various Extracellular and Signal Transduction Pathways. <i>Gene Expression</i> , 2003, 11, 13-21.	1.2	11
92	Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 605686.	3.7	11
93	Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. <i>International Journal of Oncology</i> , 2005, 26, 923.	3.3	10
94	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. <i>Frontiers in Endocrinology</i> , 2019, 10, 89.	3.5	10
95	Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. <i>Diagnostics</i> , 2019, 9, 13.	2.6	10
96	IGF-II AND IL-2 ACT SYNERGISTICALLY TO ALTER HDAC1 EXPRESSION FOLLOWING TREATMENTS WITH TRICHOSTATIN A. <i>Cytokine</i> , 2000, 12, 1104-1109.	3.2	9
97	Identifying cancer-related genes in nasopharyngeal carcinoma cell lines using DNA and mRNA expression profiling analyses. <i>International Journal of Oncology</i> , 2002, 21, 1197.	3.3	9
98	The therapeutic properties of resminostat for hepatocellular carcinoma. <i>Oncoscience</i> , 2018, 5, 196-208.	2.2	9
99	Histone deacetylase 3 represses HTLV-1 tax transcription. <i>Oncology Reports</i> , 0, , .	2.6	9
100	Novel Splicing of anIGF2Polymorphic Region in Human Adrenocortical Carcinomas. <i>Biochemical and Biophysical Research Communications</i> , 1997, 239, 878-883.	2.1	8
101	Epigenetic Methodologies for the Study of Celiac Disease. <i>Methods in Molecular Biology</i> , 2015, 1326, 131-158.	0.9	8
102	DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma. <i>International Journal of Cancer</i> , 2007, 121, 992-998.	5.1	7
103	Transcriptional Regulation of IRS5/DOK4 Expression in Non-Small-Cell Lung Cancer Cells. <i>Clinical Lung Cancer</i> , 2008, 9, 367-374.	2.6	7
104	Reactive Oxygen Species and Reactive Nitrogen Species in Epigenetic Modifications. , 2014, , 437-455.		7
105	MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1773-1791.	2.8	7
106	Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model. <i>Scientific Reports</i> , 2016, 6, 18907.	3.3	6
107	Modeling RNA secondary structure. <i>Genome Biology</i> , 2001, 2, 1.	8.8	5
108	OUP accepted manuscript. <i>Clinical Chemistry</i> , 2022, , .	3.2	5

#	ARTICLE	IF	CITATIONS
109	Epigenetic Therapy in Lung Cancer and Mesothelioma. , 2015, , 189-213.		4
110	Mesothelioma Driver Genes, Ferroptosis, and Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 1318.	2.8	4
111	Pre-clinical models of small cell lung cancer and the validation of therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 187-204.	3.4	4
112	Correlation of integrated ERG/PTEN assessment with biochemical recurrence in prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100451.	1.7	4
113	Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1073-1079.	1.0	3
114	75P Inhibition and exploitation of aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker in cisplatin resistant NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, S87.	1.1	3
115	PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?. <i>Journal of Thoracic Oncology</i> , 2016, 11, e142-e144.	1.1	3
116	P1.05-021 circRNAs: Potential Novel Biomarkers for the Early Detection of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S626-S627.	1.1	3
117	Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases. <i>Cancers</i> , 2022, 14, 981.	3.7	3
118	hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro. <i>Cancers</i> , 2021, 13, 6383.	3.7	3
119	The Potential of Epigenetic Compounds in Treating Diabetes. , 2012, , 331-367.		2
120	Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2021, 16, 14-16.	1.1	2
121	Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach. <i>Methods in Molecular Biology</i> , 2021, 2279, 145-155.	0.9	2
122	Impact and correlation of mutational load (ML) and specific mutations (mts) assessed by limited targeted profiling (LTP) with PD-L1 tumour expression (exp) in resected non-small cell lung carcinoma (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11587-11587.	1.6	2
123	Gene Expression Profiling of Human Adipocyte Responses to Insulin and IGF-I Signalling. <i>The Open Diabetes Journal</i> , 2009, 2, 5-17.	0.4	2
124	Tumor proteomics. <i>Genome Biology</i> , 2001, 2, 1.	8.8	1
125	Altered expression of low affinity insulin-like growth factor binding protein related proteins in hepatoblastoma. <i>International Journal of Molecular Medicine</i> , 2002, 9, 645.	4.0	1
126	Epigenetic therapy for cisplatin resistance in non-small-cell lung cancer: the way forward?. <i>Lung Cancer Management</i> , 2013, 2, 1-4.	1.5	1

#	ARTICLE	IF	CITATIONS
127	Epigenetics of Cisplatin Resistance. , 2015, , 613-637.		1
128	70P Identification of a novel microRNA signature: Potential diagnostic biomarkers and predictors of cisplatin response?. Journal of Thoracic Oncology, 2016, 11, S85.	1.1	1
129	Epigenetic Regulation of Chemokine/Chemokine Receptor Expression. Methods in Molecular Biology, 2013, 1013, 185-201.	0.9	1
130	Squaring the circle: sponging microRNAs in gastric cancer. Translational Cancer Research, 2019, 8, S183-S187.	1.0	1
131	Finding mutations in your favorite gene. Genome Biology, 2001, 2, 1.	8.8	0
132	More mouse SNPs. Genome Biology, 2001, 2, 1.	8.8	0
133	Collecting splice variants. Genome Biology, 2001, 2, 1.	8.8	0
134	Prostate gene expression. Genome Biology, 2001, 2, 1.	8.8	0
135	Human-fly homologies. Genome Biology, 2001, 2, 1.	8.8	0
136	Asthma genetics. Genome Biology, 2001, 2, 1.	8.8	0
137	Transgenic and targeted mouse mutation database. Genome Biology, 2001, 2, 1.	8.8	0
138	COPEing with cytokines. Genome Biology, 2001, 2, 1.	8.8	0
139	Biovalley initiative. Trends in Genetics, 2001, 17, 132.	6.7	0
140	The Canadian biotech initiative. Trends in Genetics, 2001, 17, 251.	6.7	0
141	The Janus Serum Bank: forward thinking allows retrospective analysis. Trends in Genetics, 2001, 17, 316.	6.7	0
142	PartsList: a structural genomics resource. Trends in Genetics, 2001, 17, 316-317.	6.7	0
143	A new oncogenic FGF. Trends in Genetics, 2001, 17, 317.	6.7	0
144	Immunophenotyping leukemia by microarray. Trends in Genetics, 2001, 17, 442.	6.7	0

#	ARTICLE	IF	CITATIONS
145	Homology recognition: a FUGUE in a major key. Trends in Genetics, 2001, 17, 495.	6.7	0
146	SNP decisions. Trends in Genetics, 2001, 17, 495.	6.7	0
147	Neuroblastoma breakthrough. Trends in Genetics, 2001, 17, 565.	6.7	0
148	HACKing away at disease. Trends in Genetics, 2001, 17, 565.	6.7	0
149	Comparative bacteriology. Trends in Genetics, 2001, 17, 626.	6.7	0
150	Morning-after skin repair?. Trends in Genetics, 2001, 17, 626.	6.7	0
151	Picking your SNPs. Trends in Genetics, 2001, 17, 627.	6.7	0
152	MicroRNA in Oncogenesis. , 2012, , 89-110.		0
153	67P Investigation of the interaction between non-small cell lung cancer cells and immortalised normal bronchial epithelial cells. Journal of Thoracic Oncology, 2016, 11, S83-S84.	1.1	0
154	68P Inflammatory mediated mechanisms of cisplatin resistance in non-small cell lung cancer. Journal of Thoracic Oncology, 2016, 11, S84.	1.1	0
155	P2.01-031 CCL Chemokines May Play an Important Role in Cisplatin Resistance. Journal of Thoracic Oncology, 2017, 12, S803-S804.	1.1	0
156	P2.01-066 PD-L1 Tumor Expression and Its Effect on Overall Survival among Patients with Resected Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S827.	1.1	0
157	P2.03a-063 Small Molecule Cancer Stemness Inhibitor, BBI608, Restores Cisplatin Sensitivity in Resistant NSCLC. Journal of Thoracic Oncology, 2017, 12, S927-S928.	1.1	0
158	P2.03a-064 Inhibition and Exploitation of Aldehyde Dehydrogenase 1 as a Cancer Stem Cell Marker to Overcome Cisplatin Resistant NSCLC. Journal of Thoracic Oncology, 2017, 12, S928.	1.1	0
159	P3.01-042 Lung Cancer Cells Can Stimulate Functional and Genotypic Modifications in Normal Bronchial Epithelial Cells. Journal of Thoracic Oncology, 2017, 12, S1145.	1.1	0
160	P3.03-021 When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. Journal of Thoracic Oncology, 2017, 12, S1356-S1357.	1.1	0
161	MA02.02 A Novel 5-miR Signature Shows Promise as a Diagnostic Tool and as a Predictor of Cisplatin Response in NSCLC. Journal of Thoracic Oncology, 2017, 12, S348-S349.	1.1	0
162	P3.01-064 The Overexpression and Cleavage of SASH1 by Caspase-3 Stimulates Cell Death in Lung Cancer Cells. Journal of Thoracic Oncology, 2017, 12, S1158-S1159.	1.1	0

#	ARTICLE	IF	CITATIONS
163	We're Stressed Out: BETting on Oxidative Stress?. BioEssays, 2018, 40, e1800049.	2.5	0
164	The Potential of Epigenetic Compounds in Treating Diabetes. , 2018, , 489-547.		0
165	Epigenetic Targeting of Vascular Endothelial Growth Factor (VEGF) Receptors. , 2019, , 211-231.		0
166	Targeting Diabetes Pathogenesis via Histone Deacetylases. Targeted Protein Database, 0, , .	0.0	0
167	Epigenetic Targeting of Vascular Endothelial Growth Factor (VEGF) Receptors. , 2017, , 1-21.		0
168	The "eyes" have it? "intra- and inter-observer reproducibility of the PD-L1 companion diagnostic assay. Translational Cancer Research, 2017, 6, S1027-S1029.	1.0	0